LXEO — Lexeo Therapeutics, Inc. Common Stock stock price, charts and financials

QT37Lexeo Therapeutics, Inc. Common Stock

Latest market price

4.20

+0.07+1.69%

Overview Short InterestFilings

LXEOQT37Lexeo Therapeutics, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

4.20+1.69%

Loading chart...

Signal & projected range

Gap down — mean-reversionHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	8.90%	Shs Outstand	78.52M	Perf Week	-11.37%

Market Cap	324.29M	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-1.87%	Shs Float	47.42M	Perf Month	-7.19%

Enterprise Value	259.89M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	34.48%	Perf Quarter	-27.54%

Income	-84.64M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	19.85	Perf Half Y	-45.44%

Sales	0.00	P/B	1.45	EPS next Y	-10.51%	ROA	-34.95%	Short Interest	16.35M	Perf YTD	-58.41%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-47.48%	52W High	11.18 -62.42%	Perf Year	-11.18%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-40.94%	52W Low	4.10 2.48%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.27% 6.86%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	53.07%	Oper. Margin	0.00%	ATR (14)	0.32	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	14.16	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	37.03	Recom	1.83

Dividend Gr. 3/5Y	-	Current Ratio	14.16	EPS Q/Q	74.75%	SMA20	-11.08%	Beta	1.72	Target Price	21.13

Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-12.18%	Rel Volume	0.80	Prev Close	4.13

Employees	59	LT Debt/Eq	0.02	Earnings	Aug 13	SMA200	-40.41%	Avg Volume	886.47K	Price	4.20

IPO Date	Nov 03, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	19.13% -	Net Debt/EBITDA	0.76	Volume	709,341	Change	1.69%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jan-13-26	Reiterated	HC Wainwright & Co.	Buy	$13 → $10
Dec-17-25	Initiated	Raymond James	Strong Buy
Dec-10-25	Reiterated	Oppenheimer
Nov-20-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-25	Reiterated	HC Wainwright & Co.	Buy	$15 → $13
Oct-15-25	Initiated	Guggenheim	Buy
Oct-07-25	Reiterated	HC Wainwright & Co.	Buy	$15
Oct-07-25	Reiterated	Leerink Partners	Outperform
Oct-07-25	Reiterated	Chardan Capital	Buy
Jun-12-24	Initiated	Baird	Outperform

Latest News

Jul-27-26

Jul-27-2604:31PM

A Deeper Dive Into Design TherapeuticsSeekingAlpha

Jul-10-26

Jul-10-2608:03AM

Fermi, Delta Air Lines And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga

Jun-30-26

Jun-30-2605:32PM

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia TranscriptSeekingAlpha

Jun-25-26

Jun-25-2610:54AM

JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9Benzinga

Jun-22-26

Jun-22-2608:30AM

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And TimelineSeekingAlpha

Jun-17-26

Jun-17-2604:04PM

Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA CardiologyBenzinga

Jun-15-26

Jun-15-2603:52PM

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call TranscriptSeekingAlpha

01:01PM

Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call - SlideshowSeekingAlpha

11:32AM

Why Is Lexeo Therapeutics Stock Gaining Monday?Benzinga

07:04AM

Lexeo Therapeutics Finalized SUNRISE-FA Pivotal Trial Protocol And Statistical Analysis Plan Intended To Provide Clinical Evidence To Support Submission FDA Application For Gene Therapy Candidate LX2006 Under The Accelerated Approval Pathway In 2028Benzinga

Company

Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020
Total Revenue	0	0	0	1	2	1
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0
Gross Profit	0	0	0	1	2	1
Selling, General and Administrative Excl. Other	45	32	15	12	7	1
Research and Development	64	74	53	49	45	4
Other Operating Expense	0	0	1	0	0	0
Operating Income	-109	-106	-69	-61	-51	-5
Interest Expense	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—
Non-Operating Income (Expense)	10	8	2	1	0	0
Net Income Before Taxes	-100	-98	-66	-59	-51	-5
Income Taxes	0	0	0	0	0	0
Consolidated Net Income	-100	-98	-66	-59	-51	-5
Net Income From Continuing Operations	-100	-98	-66	-59	-51	-5
Net Income	-100	-98	-66	-59	-51	-5
EPS (Recurring)	-1.86	-3.09	-2.49	-2.36	-2.01	-0.20
EPS (Basic, Before Extraordinaries)	-1.86	-3.09	-2.49	-2.36	-2.01	-0.20
EPS (Diluted)	-1.86	-3.09	-2.49	-2.40	-2.01	-0.20
EBITDA	-98	-96	-64	-58	-51	-5
Other After Tax Adjustments	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—
Gross Margin	—	—	—	100.00	100.00	100.00
Operating Margin	—	—	—	-6,100.00	-2,550.00	-500.00
Net Margin	—	—	—	-5,900.00	-2,550.00	-500.00
Shares Outstanding	54	32	27	25	25	25
Market Capitalization	536	211	362	—	—	—
Operating Lease Expense	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Townsend Richard Nolan	Chief Executive Officer	Jul 01 '26	Sale	4.48	25,947	116,243	377,817	Jul 01
Otero Jose Manuel	Chief Operating Officer	Jul 01 '26	Sale	4.48	4,666	20,904	137,482	Jul 01
Bhalla Narinder Pal	Chief Medical Officer	Jul 01 '26	Sale	4.42	22,306	98,593	82,194	Jul 01
Tamayo Louis Edward	Chief Financial Officer	Jul 01 '26	Sale	4.49	4,641	20,838	97,024	Jul 01
Otero Jose Manuel	Chief Operating Officer	May 18 '26	Sale	5.07	1,302	6,606	130,088	May 20
Townsend Richard Nolan	Chief Executive Officer	May 18 '26	Sale	5.06	3,342	16,927	336,764	May 20
Townsend Richard Nolan	Chief Executive Officer	Apr 06 '26	Sale	5.69	55,000	313,137	340,106	Apr 07
Otero Jose Manuel	Chief Operating Officer	Feb 18 '26	Sale	6.40	3,016	19,294	125,460	Feb 20
Townsend Richard Nolan	Chief Executive Officer	Feb 18 '26	Sale	6.38	10,173	64,924	392,483	Feb 20
Otero Jose Manuel	Chief Operating Officer	Nov 18 '25	Sale	9.27	721	6,684	63,476	Feb 20
Adler Eric	Chief Medical Officer	Nov 18 '25	Sale	9.27	615	5,701	72,646	Nov 20
Townsend Richard Nolan	Chief Executive Officer	Nov 18 '25	Sale	9.27	1,127	10,447	240,991	Nov 20
See Tai Sandi	Chief Development Officer	Nov 18 '25	Sale	9.27	386	3,578	65,476	Nov 20
Robertson Jenny	Chief Legal Officer	Nov 18 '25	Sale	9.27	549	5,089	68,381	Nov 20
Otero Jose Manuel	Chief Technical Officer	Aug 18 '25	Sale	5.60	3,569	19,978	60,372	Nov 20

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.